Seeking Alpha's Michael Bryant waxes positively about Seattle Genetics prospects for the next few years and recommends it as an investment candidate. This is largely based on the Company's success with SGN-35 and its promising collaboration with Millenium (Takeda) with the phase III drug for the treatment of relapsing Hodgkin's lymphoma.
SGN appears to be in good cash position, has a late stage candidate which looks like it will gain approval, is managing its burn rate -- and has promising "empowered antibody" technology for oncology -- a hot area. It may also be an attractive acquisition candidate given its promise and the faltering pipelines of many in Big Pharma -- who have the cash but no pipeline candidates and a dire revenue need in the short term.
Posted by Bruce Lehr December 30th 2010.
Comments